Malignant Mesothelioma, Advanced
1 clinical trials · Condition
◉ Watch Malignant Mesothelioma, Advanced
| Record | Firm | Date |
|---|---|---|
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
Track Malignant Mesothelioma, Advanced automatically
Every clearance here is in the API, with alerts when new ones post.